[data control] what are the risks of anti infective drugs?

Source: on December 7, 2015, the proportion of drugs in public hospitals will be reduced to 30% What will happen? Obviously, many drugs need to be coarsened So, here comes the question! Which drugs will leave the hospital? Systemic anti infectives are the largest category in the hospital market, accounting for 18.7% of the market in 2014 Moreover, under the multiple restrictions of "anti drug restriction order", public hospital fee control requirements and prohibition of outpatient infusion, the first category is likely to be the first target At present, in the grade hospitals, the proportion of systemic anti infective drugs for injection is more than 80% both in terms of sales volume and sales volume It is worth noting that the proportion of sales volume of systemic anti infective drugs for injection is larger than that of sales volume This is because the average price of systemic anti infective drugs for injection is lower due to the large number of manufacturers of the same variety and fierce price competition In terms of dosage form, the systemic anti infective drugs with the highest sales volume and sales volume in grade hospitals are all powder injection, accounting for more than 50% of the total Among the top 5 dosage forms, four are for injection These will be the most affected part of the outpatient "transfusion ban" Systemic anti infective drugs include systemic anti bacterial drugs, systemic anti viral drugs, systemic anti fungal drugs, immune serum and immunoglobulin, anti Mycobacterium drugs and vaccines Among them, the sales of systemic antibiotics accounted for the largest proportion, accounting for 87% The price range of systemic anti infectives is relatively concentrated, and the sales volume of products below 50 yuan accounts for nearly 69% of the market share But from the perspective of growth trend, the lower the price, the lower the growth rate Systemic anti infective drugs have another feature in price: the average price of drugs taken internally is higher than that of injected drugs This point has been mentioned before, but it can be found from the comparison of these two types of drug routes, drug sales and sales volume In terms of sales volume, the proportion of drugs for internal and injection with higher price (more than 50 yuan) is not far from each other, but in terms of sales volume, the difference is quite large In this case, even if transfusion is forbidden in outpatient department, the systemic anti infective drugs for injection used in outpatient department are unlikely to be directly converted to oral drugs because the price is higher, which is not conducive to the control of drug proportion and the control of proportion of anti infective drugs prescribed in outpatient department In this case, the following situations are more likely to occur: disposable injection drugs can be used and directly cut off; anti infective drugs must be needed, and the cost-effective oral drugs should be changed from injection drugs to more cost-effective ones, so that the price is moderate (20-50 Yuan), but there may be opportunities for better quality local brand drugs or exclusive products; there is also a situation in which anti infective drugs are replaced by traditional Chinese medicines, such as Pudilan, Shuanghuanglian, Lanqin, etc As for in-patient medication, injection is still the main type, but because in-patients are often in a more serious condition, and the efficacy of anti infective drugs is higher, so doctors will prefer products with definite efficacy and high price when choosing drugs - but because there are still requirements for cost control, the exclusive products with price of 50-100 yuan will be more beneficial